arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

EXAGEN INC.

XGN
$7.59 ▼ -0.94 (-11.02%) at close
Healthcare ·Services-Medical Laboratories ·USServices-Medical Laboratories
35 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

EXAGEN INC. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $183.4M
Dividend Yield —
Revenue Growth 15.9% ↗
Op. Margin -8.6% ↗
ROIC -3.9% ↗
FCF / Share $0.14 ↗
Trailing P/E —
Price / Book 15.0x
FCF Yield 1.9%
Debt / Equity 1.87
info Valuation on last close. End-of-day price, Nov 5, 2026.

35-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$19.94M
↑ +15.9% —
Net Income Profit after all expenses
$-3.97M
↓ -5.7% —
Operating Margin Operating profit as % of sales
-8.6%
↑ +56.2% 10th
FCF / Share Free cash flow per share
$0.14
↑ +131.9% —
Long-Term Debt Long-term obligations
$22.84M
— -0.1% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
9
Returns ↓
7
Financial Health ↑
29
Cash Quality ↓
49

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 9 years · 35 quarters